Umecrine Cognition Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5.54M

  • Investors
  • 8

Umecrine Cognition General Information

Description

Developer of pharmaceutical drugs designed to treat cognitive neurological disorders. The company offers drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation, a brain distortion that can lead to severely impaired cognition and fatigue, enabling healthcare industries to directly address the neurocognitive signs and symptoms of hepatic encephalopathy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Karolinska Institutet Science Park
  • Nanna Svartz väg 6A
  • 171 65 Solna
  • Sweden
+46 070-918
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Karolinska Institutet Science Park
  • Nanna Svartz väg 6A
  • 171 65 Solna
  • Sweden
+46 070-918

Umecrine Cognition Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Umecrine Cognition Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 14-Jul-2025 $5.54M Completed Clinical Trials - Phase 2
9. Accelerator/Incubator Completed Clinical Trials - Phase 2
8. Later Stage VC 17-Nov-2023 Completed Clinical Trials - Phase 2
7. Debt - General 28-Mar-2023 Completed Clinical Trials - Phase 2
6. Later Stage VC 14-Sep-2022 Completed Clinical Trials - Phase 2
5. Later Stage VC 14-Jul-2021 Completed Clinical Trials - Phase 2
4. Later Stage VC 31-Dec-2019 Completed Clinical Trials - Phase 2
3. Later Stage VC 04-Oct-2017 Completed Clinical Trials - Phase 2
2. Later Stage VC 22-Nov-2016 $4.96M $5.4M Completed Clinical Trials - Phase 2
1. Early Stage VC 31-Dec-2011 $438K $438K Completed Startup
To view Umecrine Cognition’s complete valuation and funding history, request access »

Umecrine Cognition Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
Preference
Preference
Preference 199,950 $18.71 $18.71 1x $18.71 39.59%
Preference 20,833 $16.84 $16.84 1x $16.84 4.13%
To view Umecrine Cognition’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Umecrine Cognition Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical drugs designed to treat cognitive neurological disorders. The company offers drugs for the t
Drug Discovery
Solna, Sweden
1 As of 2026

Solna, Sweden
 

Huddinge, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Umecrine Cognition Competitors (3)

One of Umecrine Cognition’s 3 competitors is Dilafor, a Venture Capital-Backed company based in Solna, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dilafor Venture Capital-Backed Solna, Sweden
AlzeCure Pharma Corporate Backed or Acquired Huddinge, Sweden
Scandinavian Biopharma Venture Capital-Backed Solna, Sweden
You’re viewing 3 of 3 competitors. Get the full list »

Umecrine Cognition Patents

Umecrine Cognition Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025252724-A1 Novel pharmaceutical formulation of golexanolone Pending 04-Jun-2024
WO-2025252725-A1 Novel pharmaceutical formulation of golexanolone Pending 04-Jun-2024
EP-4389129-A1 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia Inactive 22-Dec-2022
US-20260207625-A1 New medical use of 3a-ethynyl-3ß hydroxyandrostan-17-one oxime Pending 22-Dec-2022
EP-4637782-A1 New medical use of 3alpha-ethynyl-3beta hydroxyandrostan 17-one oxime Pending 22-Dec-2022 A61K31/568
To view Umecrine Cognition’s complete patent history, request access »

Umecrine Cognition Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Umecrine Cognition Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ribbskottet Corporation
AB Ility Venture Capital Minority
Almi Invest Venture Capital Minority
Fort Knox Family Office Minority
KDventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Umecrine Cognition FAQs

  • When was Umecrine Cognition founded?

    Umecrine Cognition was founded in 2006.

  • Where is Umecrine Cognition headquartered?

    Umecrine Cognition is headquartered in Solna, Sweden.

  • What is the size of Umecrine Cognition?

    Umecrine Cognition has 1 total employees.

  • What industry is Umecrine Cognition in?

    Umecrine Cognition’s primary industry is Drug Discovery.

  • Is Umecrine Cognition a private or public company?

    Umecrine Cognition is a Private company.

  • What is Umecrine Cognition’s current revenue?

    The current revenue for Umecrine Cognition is .

  • How much funding has Umecrine Cognition raised over time?

    Umecrine Cognition has raised $28.2M.

  • Who are Umecrine Cognition’s investors?

    Ribbskottet, AB Ility, Almi Invest, Fort Knox, and KDventures are 5 of 8 investors who have invested in Umecrine Cognition.

  • Who are Umecrine Cognition’s competitors?

    Dilafor, AlzeCure Pharma, and Scandinavian Biopharma are competitors of Umecrine Cognition.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process